Judge Dismissed Most AbbVie Antitrust Claims

A federal court in Illinois allowed a single claim regarding Humira pricing to proceed in a class action lawsuit.

Updated on Oct. 2, 2026 in Healthcare

Bold flat-color editorial illustration of a single pharmaceutical vial against a geometric grid, representing antitrust legal action. — A federal judge in Illinois dismissed most claims in an antitrust class action lawsuit against AbbVie, leaving one pricing claim to proceed. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies face legal accountability for alleged price inflation of their drugs?

An Illinois federal judge dismissed the majority of claims in an antitrust class action against pharmaceutical giant AbbVie. The court ruled that one claim regarding artificially inflated Humira prices may proceed.

Why it matters

The ruling narrows the legal scope of allegations that AbbVie unlawfully stifled competition in the adalimumab market. By allowing the pricing claim to continue, the court has ensured the litigation will examine how the company managed Humira market access.

The court dismissed all but one claim in a putative class action brought by a sheet metal worker health plan against AbbVie. The remaining legal action centers on whether the company artificially inflated prices for the drug Humira.

The players

AbbVie

AbbVie is a global research-based biopharmaceutical company that produces Humira, a widely prescribed medication for autoimmune diseases.

The details

The court issued its ruling on a motion to dismiss, finding that the plaintiff provided sufficient evidence to argue that AbbVie stifled competition within the adalimumab market. While most arguments were struck down, the court determined the pricing allegations warrant further judicial review.

October 1, 2026: The federal judge issued the ruling on the motion to dismiss.

Law
Oct. 6
Illinois Judge Approved $200 Million Antitrust Deal
Law
Sept. 29
Illinois Appellate Court Denied Surplus Equity Claim
Cybersecurity
Sept. 30
Court Denied Union Pacific BIPA Immunity

Market Landscape

This judicial decision represents a significant checkpoint in the long-standing legal battle over market dominance in the adalimumab space. The ruling shifts the focus toward pricing practices as the primary contention point against the industry leader.

While the litigation continues, consumers and health plans will watch to see if this ruling leads to changes in how major drug manufacturers set prices for high-demand medications. The outcome could eventually impact the cost of treatments for patients reliant on biologics.

The takeaway

Legal challenges regarding pharmaceutical pricing remain a central issue for employer-sponsored health plans seeking to control costs. Organizations should monitor these court rulings as they can influence long-term drug pricing strategies.